Format

Send to

Choose Destination
Cancer Lett. 2013 Dec 1;341(2):132-8. doi: 10.1016/j.canlet.2013.08.008. Epub 2013 Aug 11.

Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions.

Author information

1
Indiana University School of Medicine, Indianapolis, IN, USA.

Abstract

Pancreatic ductaladeno carcinoma (PDAC) is a deadly cancer characterized by multiple molecular alterations, the presence of an intense stroma, poor perfusion, and resistance to therapy. In addition to standard imaging techniques, experimental imaging strategies, such as those utilizing molecular probes, nanoparticle-based agents, and tagged antibodies are actively being explored experimentally. It is hoped that advances in these technologies will allow for detecting PDAC at an early stage, and could serve to validate experimental therapies, rapidly identify non-responders, and assist in the design of novel therapeutic strategies tailored to the patient's molecular profile.

KEYWORDS:

Molecular imaging; PDAC; Ultrasonography

PMID:
23941833
PMCID:
PMC3902085
DOI:
10.1016/j.canlet.2013.08.008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center